Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Ampio Pharmaceuticals, Inc. | ampe-20191231ex321b3b088.htm |
| EX-31.2 - EX-31.2 - Ampio Pharmaceuticals, Inc. | ampe-20191231ex3120db316.htm |
| EX-31.1 - EX-31.1 - Ampio Pharmaceuticals, Inc. | ampe-20191231ex311d1ebaa.htm |
| EX-23.1 - EX-23.1 - Ampio Pharmaceuticals, Inc. | ampe-20191231ex2310a0620.htm |
| EX-14.1 - EX-14.1 - Ampio Pharmaceuticals, Inc. | ampe-20191231ex141da1b56.htm |
| EX-10.11 - EX-10.11 - Ampio Pharmaceuticals, Inc. | ampe-20191231ex1011ca76e.htm |
| EX-4.5 - EX-4.5 - Ampio Pharmaceuticals, Inc. | ampe-20191231ex45b6a1a6a.htm |
| 10-K - 10-K - Ampio Pharmaceuticals, Inc. | ampe-20191231x10k.htm |
EXHIBIT 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in Ampio Pharmaceuticals, Inc.’s Registration Statements on Form S-8 (File No. 333-235853) and Form S-3 (File No. 333-217094) of our report dated March 18, 2019, relating to the financial statements, which includes an explanatory paragraph regarding the substantial doubt about Ampio Pharmaceuticals, Inc.’s ability to continue as a going concern, which appears in this Annual Report on Form 10-K.
|
|
/s/ Plante & Moran, PLLC |
|
|
|
|
February 21, 2020 |
|
|
Denver, Colorado |
|
|
|
|